Publications

  1. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017 Oct 20; 35 (30):3391-3400 Epub 2017 Aug 30
    View PubMed
  2. Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017 Sep 05 Epub 2017 Sept 05
    View PubMed
  3. Gast KC, Allen SV, Ruddy KJ, Haddad TC. Novel approaches to support breast cancer survivorship care models. Breast. 2017 Aug 24; 36:1-13.
    View PubMed
  4. Ruddy KJ, Van Houten HK, Sangaralingham LR, Freedman RA, Thompson CA, Hashmi SK, Jemal A, Haddad TC, Mougalian S, Herrin J, Gross C, Shah N. Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat. 2017 Aug; 164: (3)515-525.
    View PubMed
  5. Nowsheen S, Viscuse PV, O'Sullivan C, Sandhu NP, Haddad TC, Blaes A, Klemp J, Nhola L, Herrmann J, Ruddy KJ. Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients with Breast Cancer Clinical Trials (PF PEDDI, SECTION EDITOR).2017;
  6. Haddad TC, Goetz , Matthew. Treating ER-positive, HER2-negative metastatic breast cancer ASCO Daily News; https://am.asco.org/treating-er-positive-her2-negative-metastatic-breast-cancer.2017;
  7. Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 Jun; 163: (3)535-544.
    View PubMed
  8. Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79: (6)1221-1227.
    View PubMed
  9. Park JW, Liu MC, Yee D, Yau C, van 't Veer, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375: (1)11-22.
    View PubMed
  10. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375: (1)23-34.
    View PubMed
  11. Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer. 2016 Feb 01; 122: (3)378-85.
    View PubMed
  12. Kasi PM, Hieken TJ, Haddad TC. Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. Case Rep Oncol. 2016 Jan-Apr; 9: (1)33-8.
    View PubMed
  13. Blaes AH, Fenner D, Bachanova V, Torkelson C, Geller M, Haddad T, Shanley R, Kreitzer MJ. Mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation Journal of Community and Supportive Oncology. 2016; 14: (8)351-8.
  14. Koehler LA, Blaes AH, Haddad TC, Hunter DW, Hirsch AT, Ludewig PM. Movement, Function, Pain, and Postoperative Edema in Axillary Web Syndrome. Phys Ther. 2015 Oct; 95: (10)1345-53.
    View PubMed
  15. Pankratz VS, Winham SJ, Dupont WD, Vierkant RA, Frank RD, Frost MH, Vachon C, Ghosh K, Hieken TJ, Carter JM, Haddad TC, Denison L, Visscher DW, Hartmann LC, Radisky DC. A new model for predicting breast cancer risk in women with atypical hyperplasia. J Clin Oncol. 2015 Oct; 33: (28_suppl)2.
    View PubMed
  16. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21 (13):2911-5 Epub 2015 Feb 24
    View PubMed
  17. Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015 May; 22: (5)1408-15.
    View PubMed
  18. Blaes A, Duprez D, Defor T, Shanley R, Beckwith H, Haddad T, Potter D, Yee D, Sanghavi K, Jacobson P. Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus. 2015; 4:32.
    View PubMed
  19. D'Assoro AB, Haddad T, Galanis E. Aurora-A Kinase as a Promising Therapeutic Target in Cancer. Front Oncol. 2015; 5:295 Epub 2016 Jan 06
    View PubMed
  20. Herrmann J, Herrmann SM, Haddad TC. New-onset heart failure in association with severe hypertension during trastuzumab therapy. Mayo Clin Proc. 2014 Dec; 89: (12)1734-9.
    View PubMed
  21. Koehler LA, Hunter DW, Haddad TC, Blaes AH, Hirsch AT, Ludewig PM. Characterizing axillary web syndrome: ultrasonographic efficacy. Lymphology. 2014 Dec; 47(4):156-63.
    View PubMed
  22. Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, Ingle JN, Galanis E, D'Assoro AB. Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERalpha expression in initially ERalpha+ breast cancer cells. PLoS One. 2014; 9: (5)e96995.
    View PubMed
  23. Scanlon M, Blaes A, Geller M, Majhail NS, Lindgren B, Haddad T. Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer. J Cancer. 2012; 3:217-25. Epub 2012 May 16.
    View PubMed
  24. Blaes AH, Kreitzer MJ, Torkelson C, Haddad T. Nonpharmacologic complementary therapies in symptom management for breast cancer survivors. Semin Oncol. 2011 Jun; 38(3):394-402.
    View PubMed
  25. Jang S, Prizment A, Haddad T, Robien K, Lazovich D. Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study. J Cancer Surviv. 2011 Jun; 5(2):115-22. Epub 2010 Sep 02.
    View PubMed
  26. Bandhakavi S, Van Riper SK, Tawfik PN, Stone MD, Haddad T, Rhodus NL, Carlis JV, Griffin TJ. Hexapeptide libraries for enhanced protein PTM identification and relative abundance profiling in whole human saliva. J Proteome Res. 2011 Mar 4; 10(3):1052-61. Epub 2011 Jan 14.
    View PubMed
  27. Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat. 2010 Jun; 121(2):273-9. Epub 2010 Mar 30.
    View PubMed
  28. Patnaik MM, Haddad T, Morton CT. Pregnancy and thrombophilia. Expert Rev Cardiovasc Ther. 2007 Jul; 5(4):753-65.
    View PubMed
  29. Haddad T, Yee D. Can genes predict the future? Minnesota Physician. 2007; 21:26.
  30. Haddad T, Yee D. Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncol. 2006 Feb; 2(1):101-10.
    View PubMed
  31. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006; 118(5):555-68. Epub 2006 Jan 04.
    View PubMed
  32. Lawrence JB, Bale LK, Haddad TC, Clarkson JT, Conover CA. Characterization and partial purification of the insulin-like growth factor (IGF)-dependent IGF binding protein-4-specific protease from human fibroblast conditioned media. Growth Horm IGF Res. 1999 Feb; 9(1):25-34.
    View PubMed
  33. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res. 1997 Oct; 3(10):1713-20.
    View PubMed
  34. Haddad T, Conover C. Insulin and IL-4 desensitization to the mitorgenic effects of IGF-I. J Biochem. 1997; 272(31).